Novocure Limited (Novocure)

Oncology Corporate Profile

HQ Location

195 Commerce Way
Portsmouth, NH 3801

Company Description

Novocure is dedicated to the development of tumor treating fields (TTF) therapy, a new weapon for patients and physicians in the battle against cancer. TTF therapy is a breakthrough anti-mitotic treatment that attempts to slow or reverse tumor progression by inducing tumor cell death prior to division. Physicians deliver TTF therapy using a portable, non-invasive medical device.


Brand Generic Indication
NovoTTF-100A Systemâ„¢ medical deviceThe NovoTTF-100A System is intended as a treatment for adult patients (22
years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device
is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
NovoTTF-100A System? (+ temozolomide)tumor treating fields (TTF) therapy1st line metastatic Glioblastoma Multiforme (GBM)III
NovoTTF-100L System? (+ pemetrexed)tumor treating fields (TTF) therapyPancreatic cancerI
NovoTTF-100L System? (+ pemetrexed)tumor treating fields (TTF) therapy1st line metastatic Non Small Cell Lung Cancer (NSCLC)II

View additional information on product candidates here »


Recent News Headlines

There are no news items to display